A5046452161- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Apelin-related biomedical research
- Ferroptosis and cancer prognosis
- Pancreatitis Pathology and Treatment
- Chronic Kidney Disease and Diabetes
- Heart Failure Treatment and Management
- Iron Metabolism and Disorders
- Metabolism, Diabetes, and Cancer
- Gastrointestinal motility and disorders
- Cardiovascular Function and Risk Factors
- Lipoproteins and Cardiovascular Health
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- MicroRNA in disease regulation
- Diet, Metabolism, and Disease
- Complement system in diseases
- Blood Pressure and Hypertension Studies
- Autophagy in Disease and Therapy
- Cancer-related molecular mechanisms research
- Nuclear Receptors and Signaling
- Trace Elements in Health
Hebei Medical University
2022-2025
Hebei General Hospital
2014-2025
Recently, hypoglycemic drugs belonging to sodium-glucose cotransporter 2 inhibitors (SGLT2i) have generated significant interest due their clear cardiovascular benefits for heart failure with preserved ejection fraction (HFpEF) since there are no effective that may improve clinical outcomes these patients over a prolonged period. But, the underlying mechanisms remain unclear, particularly its effects on ferroptosis, newly defined mechanism of iron-dependent non-apoptotic cell death during...
Hypertensive nephropathy is characterized by long-term damage to renal tissues chronic uncontrolled hypertension, and ultimately leads the development of fibrosis. The epithelial-mesenchymal transition (EMT) potentially contributes promotion fibrosis in kidney disease (CKD). In this study, we investigated potential roles canagliflozin (Cana) on EMT oxidative stress through its effects sirtuin 3 (SIRT3) expression. High-salt diet (HSD)-induced Dahl salt-sensitive rats hypertensive injury led...
Purpose To investigate the effects of canagliflozin (20 mg/kg) on Dahl salt-sensitive (DSS) rat gut microbiota and hypertension-induced kidney injury further explore its possible mechanism.
Heart failure with preserved ejection fraction (HFpEF) represents a challenging cardiovascular condition characterized by normal systolic function but impaired diastolic performance. Despite its increasing prevalence, therapeutic options remain limited. This study investigated the metabolic effects of canagliflozin, sodium-glucose cotransporter 2 (SGLT2) inhibitor, on cardiac and energy metabolism in HFpEF. We established rat model HFpEF using Dahl salt-sensitive rats evaluated three...
Recent studies have shown that sodium-glucose cotransporters-2 (SGLT2) inhibitors significantly improve major adverse cardiovascular events in heart failure with preserved ejection fraction (HFpEF) patients, but the exact mechanism is unknown. Ferritinophagy a special form of selective autophagy participates ferroptosis. In this study, we aimed to investigate whether ferritinophagy was activated during occurrence HFpEF, and canagliflozin (CANA) could inhibite ferritinophagy. We reared Dahl...
To investigate the effect of canagliflozin (20 mg/kg) on hepatic steatosis and atherosclerosis, further to explore its possible mechanism.Blood glucose, blood lipid, oxidative stress response inflammatory cytokines were examined by intraperitoneal glucose tolerance test ELISA assay. HE Oil Red O staining used estimate extent atherosclerosis. RNA-seq qRT-PCR potential mechanism. The effects autophagy detected using transmission electron microscopy Western blotting. endothelial...
Background: The aim of the study was to investigate protective effect canagliflozin (CANA) on myocardial metabolism and heart under stress overload further explore its possible molecular mechanism. Methods: High-salt diet used induce failure with preserved ejection fraction (HFpEF), then, physical physiological indicators were measured. cardiac function evaluated by echocardiography related indicators. Masson trichrome staining, wheat germ agglutinin, immunohistochemical staining conducted...
The aim of this study was to investigate the effect canagliflozin (CANA) on ventricular remodeling in patients with preserved ejection fraction (HFpEF) heart failure and further its possible molecular mechanisms.A high-salt diet used induce formation HFpEF model salt-sensitive rats. rats were fed CANA irbesartan, respectively. mice divided into control group, irbesartan combined drug group. After 12 weeks feeding, evaluated by measuring relevant indexes echocardiography for cardiac function....
Aims: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to ameliorate major adverse cardiovascular events in patients with heart failure preserved ejection fraction (HFpEF), but the exact mechanism is unknown. Ferroptosis a form of programmed necrosis. Herein, we verified that canagliflozin (CANA) ameliorates function HFpEF rats, partly by regulating ferroptosis, which may be activated AMPK/PGC-1α/Nrf2 signaling. Methods: An model was established and subjected CANA treatment....
Purpose: This study was aimed at investigating the effect of canagliflozin (Cana) on atherosclerosis and further exploring its potential mechanism. Methods: ApoE −/− mice were fed a Western diet (WD) randomly divided into WD group WD+Cana group. After 15 weeks treatment, serum levels fasting insulin inflammatory cytokines determined with ELISA kits. HE, Oil Red O, Masson staining used to estimate extent atherosclerosis. Immunohistochemistry, immunofluorescence, ROS staining, RT-PCR...
Objective The aim of this study was to investigate the potential importance complement system activation, with particular emphasis on alternative pathway (AP), in pathogenesis hypertensive renal damage.
Objectives This study assessed the antifibrotic effects of canagliflozin, with or without irbesartan, on renal injury in Dahl salt-sensitive (SS) rats fed a high-salt (HS) diet. Methods After preconditioning stage, SS (n = 47) were divided into five experimental groups as follows: low-salt (LS, n 7), HS 10), canagliflozin irbesartan and 10). Results The diet increased systolic blood pressure (SBP), fibrosis, fibrotic protein expression, transforming growth factor-β1 (TGF-β1)/Smad2/3 pathway...
Abstract Background Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular mortality in patients. We studied the effect of canagliflozin on cardiac remodeling and myocardial metabolism a rat model heart failure with preserved ejection fraction (HFpEF). Methods In this study, HFpEF was treated canagliflozin, blood glucose, renal function, oxidative stress indexes, lipid parameters, biochemical indexes echocardiographic left ventricular function were assessed normal control group...
Abstract Hypertension is one of the major contributors to cardiovascular and chronic kidney disease (CKD). Sodium-glucose cotransporter 2 (SGLT2) inhibitors angiotensin receptor blockers (ARBs) have become preferred treatment for patients with CKD. However, renoprotective effects combined therapy two drugs on hypertensive renal fibrosis are still largely understood. The aim this study was compare antifibrotic canagliflozin, or without irbesartan, in kidneys Dahl salt-sensitive (Dahl SS) rats...